From Wikipedia, the free encyclopedia
(Redirected from MAPKK)
Mitogen-activated protein kinase kinase
Identifiers
EC no. 2.7.12.2
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Search
PMC articles
PubMed articles
NCBI proteins

Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a dual-specificity kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

MAP2K is classified as EC 2.7.12.2.

There are seven genes:

The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. [1] The acronym MEK derives from MAPK/ERK Kinase. [2]

Role in melanoma

MEK is a member of the MAPK signaling cascade that is activated in melanoma. [3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

See also

References

  1. ^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science. 267 (5198): 682–5. Bibcode: 1995Sci...267..682D. doi: 10.1126/science.7839144. PMID  7839144. S2CID  9153074.
  2. ^ Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling. 16 (4): 374–80. doi: 10.1089/ars.2011.4034. PMC  3279717. PMID  21939387.
  3. ^ Falchook, Gerald S.; Lewis, Karl D.; Infante, Jeffrey R.; Gordon, Michael S.; Vogelzang, Nicholas J.; DeMarini, Douglas J.; Fecher, Leslie A.; et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology. 13 (8): 782–789. doi: 10.1016/S1470-2045(12)70269-3. PMC  4109286. PMID  22805292.

External links